Teri Lawver joined Dexcom (Nasdaq:DXCM) as chief commercial officer just as the company got set for a massive commercial undertaking. The FDA cleared the company’s next-generation Dexcom G7 continuous glucose monitor (CGM) in December 2022. One month later, Lawver assumed the position of CCO. Within about a month, she was set to oversee the U.S. launch […]
ADA 2023
The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions
As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space. At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for […]
Study shows health equity impact from Virta Health diabetes reversal platform
Virta Health announced that real-world data for its diabetes reversal platform demonstrated narrowing gaps in care. The company shared its data at the American Diabetes Association’s 83rd Scientific Sessions. The research highlighted its impact on health equity. It demonstrated significant health improvement and medication reduction for members in the most and least disadvantaged U.S. neighborhoods. […]
Vida Health reports positive data for virtual diabetes program in low-income populations
Vida Health announced new research demonstrating significantly lowered A1C levels with its virtual cardiometabolic program. The research highlighted use of the program in low-income Medicare Advantage members. Significantly lowered A1C levels even occurred in areas with limited income and food access. Vida Health’s study compared its members living in areas of low income and low […]
Studies back Fractyl Health diabetes reversal procedure, gene therapy
Fractyl Health announced multiple studies supporting its programs for the reversal and treatment of diabetes. Lexington, Massachusetts-based Fractyl reported data from its Revitalize 1 pivotal study and its Rejuva program. Revitalize 1 evaluates the company’s Revita endoscopic ablation procedure to reverse diabetes. Rejuva evaluates a targeted pancreatic gene therapy. The company presented its results at […]
Data supports safety and accuracy of Senseonics 365-day CGM
Senseonics (NYSE:SENS) today announced positive clinical data highlighting the effectiveness of its Eversense continuous glucose monitor (CGM). Germantown, Maryland-based Senseonics presented two studies on its latest-generation Eversense E3 at the American Diabetes Association 83rd Scientific Session. The 180-day implantable CGM received FDA approval in February of last year. The sensor is fully implantable and requires just […]
Once-weekly insulin from Novo Nordisk meets clinical trial endpoints
Novo Nordisk announced data that met primary endpoints from clinical trials investigating its once-weekly basal insulin icodec. While meeting primary endpoints, the studies also demonstrated reduced injections. These injections decreased from seven to one per week with once-daily basal insulin. Novo Nordisk presented results at the 83rd Annual Scientific Sessions of the American Diabetes Association […]
Abbott, ADA partner on therapeutic nutrition program for people with diabetes
Abbott (NYSE:ABT) and the American Diabetes Association (ADA) announced a collaboration to improve nutrition for people with diabetes. The duo aims to help better understand how diabetes technology, like continuous glucose monitoring (CGM), can help. They hope to aid people with diabetes make more informed decisions about their food and activity. Abbott develops a family […]
Dexcom aims to bring new glucose sensor to the market for people who don’t use insulin
Dexcom (Nasdaq:DXCM) today unveiled its strategy to expand access to its glucose-sensing technology for millions around the world. San Diego-based Dexcom held an Investor Day event in which it revealed plans to bring a new product to market in the U.S. in 2024. The company designed its new product for people who don’t use insulin […]
New data supports Medtronic MiniMed 780G automated insulin delivery system for children
Medtronic (NYSE:MDT) today announced positive clinical and real-world data supporting its MiniMed 780G automated insulin delivery system. The latest data sets evaluated the recently FDA-approved system across a wide range of users. They looked at younger patients, those not meeting glycemic goals and individuals using simplified meal announcement technology. Medtronic presented these results at the 83rd […]
